Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. IRWD
I

Ironwood Pharmaceuticals, Inc. (IRWD)

3.06

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
27.03.2026

Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
12.03.2026

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.

Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
06.03.2026

Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?

Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
04.03.2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide
26.02.2026

Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide

Ironwood Pharmaceuticals is downgraded from a 'Buy' to a 'Sell' due to pipeline setbacks and declining LINZESS sales. IRWD declined to exercise its option on CNP-104 for PBC after disappointing data, removing a key pipeline catalyst. LINZESS U.S. sales dropped 6% to $864.5M in 2025, casting doubt on management's bullish 2026 sales guidance of $1.125–$1.175B.

IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
26.02.2026

IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks

Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
25.02.2026

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
04.03.2026

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
25.02.2026

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full‑year 2025 results and recent business performance. “In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader for the treatment of IBS-C and CIC, surpassing 5.7.

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
02.01.2026

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming.

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
10.11.2025

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financ.